aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced the granting of inducement stock options to three new employees. The Compensation Committee approved options to purchase 62,400 shares at $5.71 per share, matching the closing price on September 3, 2025.

The options, granted under Nasdaq Listing Rule 5635(c)(4) and the company's 2022 Inducement Plan, vest over four years with 25% vesting after one year and the remaining 75% vesting monthly over three years. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with efzofitimod as its lead candidate for treating interstitial lung disease.

Positive

• Company maintains ability to attract talent with equity compensation
• Structured vesting schedule helps retain employees over 4-year period

Negative

• Potential dilution to existing shareholders from new stock options
• Additional stock-based compensation expense impact on financial statements

News Market Reaction

-2.67%

1 alert

-2.67% News Effect

On the day this news was published, ATYR declined 2.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on September 3, 2025, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

Each option vests over a period of four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting in equal monthly installments over three years, subject to the applicable employee’s continued employment with aTyr through each vesting date. The options are subject to the terms and conditions of the aTyr Pharma, Inc. 2022 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

FAQ

What stock options did aTyr Pharma (ATYR) grant to new employees in September 2025?

aTyr granted options to purchase 62,400 shares at $5.71 per share to three new employees, with a four-year vesting schedule.

How do the vesting terms work for aTyr Pharma's September 2025 inducement grants?

The options vest over 4 years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over three years.

What is aTyr Pharma's main therapeutic candidate?

aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator for treating interstitial lung disease.

What is the purpose of aTyr Pharma's inducement grants under Nasdaq Rule 5635(c)(4)?

The grants serve as an inducement material to attract new employees to aTyr Pharma, awarded outside of the company's standard equity incentive plans.